Hepatitis C treatment uptake among patients who have received opioid substitution treatment: A population-based study

PLoS ONE

Volumn 11, Issue 11, 2016, Pages

  Midgard, Håvard ^a,b   Bramness, Jørgen G ^b   Skurtveit, Svetlana ^b,c   Haukeland, John W ^d   Dalgard, Olav ^a,b  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; METHADONE; NALOXONE; NEUROLEPTIC AGENT; PEGINTERFERON; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; ALPHA INTERFERON; ANTIVIRUS AGENT; BUPRENORPHINE PLUS NALOXONE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN;

ADULT; AGE; AGED; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG USE; FEMALE; GENDER; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; OBSERVATIONAL STUDY; OPIATE SUBSTITUTION TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; DISEASE NOTIFICATION; DRUG EFFECTS; HEPACIVIRUS; MIDDLE AGED; PHYSIOLOGY; PSYCHOLOGY; REGISTER; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; VIROLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; ANTIVIRAL AGENTS; BENZODIAZEPINES; BUPRENORPHINE, NALOXONE DRUG COMBINATION; DISEASE NOTIFICATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; METHADONE; MIDDLE AGED; NORWAY; OPIATE SUBSTITUTION TREATMENT; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; REGISTRIES; RIBAVIRIN; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84995470014     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0166451     Document Type: Article

References (53)

1. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011; 378 (9791):571-83. doi: 10.1016/S0140-6736(11)61097-0 PMID: 21802134
2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of hepatology. 2014; 61(1 Suppl):S45-57.
3. Grebely J, Raffa JD, Lai C, Kerr T, Fischer B, Krajden M, et al. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. Journal of viral hepatitis. 2011; 18(1):32-41. doi: 10.1111/j.1365-2893.2010.01279.x PMID: 20196806
4. Kielland KB, Skaug K, Amundsen EJ, Dalgard O. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. Journal of hepatology. 2013; 58(1):31-7. doi: 10.1016/j.jhep.2012.08.024 PMID: 22960427
5. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nature reviews Gastroenterology & hepatology. 2013; 10(9):553-62.
6. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2013;57 Suppl 2:S80-9.
7. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2013; 56(6):806-16.
8. AASLD-IDSA. AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus. Available: http://www.hcvguidelines.org. Accessed 20 June 2016. (Archived by WebCite® at http://www.webcitation.org/6iPAiC0wA). 2015.
9. Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. The International journal on drug policy. 2015; 26(10):1028-38. doi: 10.1016/j.drugpo.2015.07.005 PMID: 26282715
10. WHO. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Available: http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/. 2016.
11. EASL. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. Journal of hepatology. 2016.
12. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, et al. Limited uptake of hepatitis C treatment among injection drug users. Journal of community health. 2008; 33(3):126-33. doi: 10. 1007/s10900-007-9083-3 PMID: 18165889
13. Grebely J, Raffa JD, Lai C, Krajden M, Kerr T, Fischer B, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. Journal of viral hepatitis. 2009; 16(5):352-8. doi: 10.1111/j.1365-2893.2009.01080.x PMID: 19226330
14. Alavi M, Raffa JD, Deans GD, Lai C, Krajden M, Dore GJ, et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver international: official journal of the International Association for the Study of the Liver. 2014; 34(8):1198-206.
15. Iversen J, Grebely J, Topp L, Wand H, Dore G, Maher L. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011. Journal of viral hepatitis. 2014; 21(3):198-207. doi: 10.1111/jvh.12129 PMID: 24438681
16. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. Journal of viral hepatitis. 2014; 21 Suppl 1:34-59.
17. Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm-volume 2. Journal of viral hepatitis. 2015; 22 Suppl 1:26-45.
18. McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver international: official journal of the International Association for the Study of the Liver. 2012; 32 Suppl 1:151-6.
19. Bruggmann P. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers. Journal of viral hepatitis. 2012; 19(12):829-35. doi: 10.1111/jvh.12008 PMID: 23205675
20. McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology. 2013; 57(4):1325-32. doi: 10.1002/hep.26246 PMID: 23315914
21. Perlman DC, Jordan AE, Uuskula A, Huong DT, Masson CL, Schackman BR, et al. An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. The International journal on drug policy. 2015.
22. Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction. 2012; 107(11):1984-95. doi: 10.1111/j.1360-0443.2012.03932.x PMID: 22564041
23. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2013; 57 Suppl 2:S39-45.
24. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology. 2004; 40(1):120-4. doi: 10.1002/hep.20279 PMID: 15239094
25. Hallinan R, Byrne A, Agho K, Dore GJ. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug and alcohol dependence. 2007; 88(1):49-53. doi: 10.1016/j.drugalcdep. 2006.09.018 PMID: 17067763
26. Krook AL, Stokka D, Heger B, Nygaard E. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. European addiction research. 2007; 13(4):216-21. doi: 10.1159/000104884 PMID: 17851243
27. Litwin AH, Harris KA Jr., Nahvi S, Zamor PJ, Soloway IJ, Tenore PL, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. Journal of substance abuse treatment. 2009; 37(1):32-40. doi: 10.1016/j.jsat.2008. 09.009 PMID: 19038524
28. Witteck A, Schmid P, Hensel-Koch K, Thurnheer MC, Bruggmann P, Vernazza P, et al. Management of hepatitis C virus (HCV) infection in drug substitution programs. Swiss medical weekly. 2011; 141: w13193. doi: 10.4414/smw.2011.13193 PMID: 21623473
29. Sasadeusz JJ, Dore G, Kronborg I, Barton D, Yoshihara M, Weltman M. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction. 2011; 106(5):977-84. doi: 10.1111/j.1360-0443.2010.03347.x PMID: 21205057
30. Alavi M, Grebely J, Micallef M, Dunlop AJ, Balcomb AC, Day CA, et al. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2013; 57 Suppl 2:S62-9.
31. Masson CL, Delucchi KL, McKnight C, Hettema J, Khalili M, Min A, et al. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. American journal of public health. 2013; 103(10):e81-8. doi: 10.2105/AJPH.2013.301458 PMID: 23947319
32. Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2013; 57 Suppl 2:S56-61.
33. Grebely J, Alavi M, Micallef M, Dunlop AJ, Balcomb AC, Phung N, et al. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction. 2016; 111(2):311-9. doi: 10.1111/add.13197 PMID: 26451534
34. Amundsen EJ, Bretteville-Jensen AL. Hard drug use in Norway. Nordic Studies on Alcohol and Drugs. 2010; 27.
35. Skretting A. BEK, Vedøy, T. F., Lund, K. E. Drug use in Norway. SIRUS report 2015. The Norwegian Institute for Alcohol and Drug Research. Available: http://wpstatic.idium.no/www.sirus.no/2015/12/ rusmidler-i-norge2015.pdf. Accessed 20 June 2016. (Archived by WebCite® at http://www. webcitation.org/6iPCCbZEJ).
36. Waal H, Busserud K, Clausen T, Skeie I, Håseth A, Lillevold H. Annual assessment of the Norwegian OMT program 2016. SERAF, University of Oslo. Avaiable: http://www.oslo-universitetssykehus.no/ SiteCollectionDocuments/Omoss/Avdelinger/Psykiskhelseogavhengighet/Rus-ogavhengighetsbehandling/NasjonalkompetansetjenesteTSB/seraf-rapport-nr-1-2016-statusrapport-2015.pdf. Accessed 20 June 2016. (Archived by WebCite® at http://www.webcitation.org/6iPCcZGfV).
37. Dalgard O, Egeland A, Ervik R, Vilimas K, Skaug K, Steen TW. [Risk factors for hepatitis C among injecting drug users in Oslo]. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke. 2009; 129(2):101-4.
38. Guidelines for ATC classification and DDD assignment 2013. WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health, Oslo, Norway. Available: http://www.whocc. no. Accessed 20 June 2016. (Archived by WebCite® at http://www.webcitation.org/6iPBKwpRP).
39. Waal H. Merits and problems in high-threshold methadone maintenance treatment. Evaluation of medication-assisted rehabilitation in Norway 1998-2004. European addiction research. 2007; 13(2):66-73. doi: 10.1159/000097935 PMID: 17356277
40. National guidelines for opioid substitution treatment 2010. The Norwegian Directorate of Health. Available: https://helsedirektoratet.no/Lists/Publikasjoner/Attachments/100/IS-1701-Legemiddelassistertrehabilitering-ved-opioidavhengighet.pdf. Accessed 20 June 2016. (Archived by WebCite® at http:// www.webcitation.org/6iPB3f7a0).
41. Bell H, Dalgard O, Bjoro K, Hellum KB, Myrvang B. [Treatment of chronic hepatitis C]. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke. 2002; 122(9):926-8.
42. Norwegian Institute of Public Health. Available: https://wwwfhino/nettpub/smittevernveilederen/ sykdommer-a-a/hepatitt-c-veileder-for-helsepers/-forekomst-i-norge. 2016.
43. Dalgard O, Bjøro K, Mland A, Konopski Z, Karlsen L, Sandvei P, et al. Norwegian guidelines for assessment and treatment of hepatitis C infection 2015. Available: http://www.hepatittfag.no. Accessed
44. June 2016. (Archived by WebCite® at http://www.webcitation.org/6iPBWGkvc).
45. Bukten A, Skurtveit S, Waal H, Clausen T. Factors associated with dropout among patients in opioid maintenance treatment (OMT) and predictors of re-entry. A national registry-based study. Addictive behaviors. 2014; 39(10):1504-9. doi: 10.1016/j.addbeh.2014.05.007 PMID: 24960556
46. Kielland KB, Amundsen EJ, Dalgard O. HCV treatment uptake in people who have injected drugs-observations in a large cohort that received addiction treatment 1970-1984. Scandinavian journal of gastroenterology. 2014; 49(12):1465-72. doi: 10.3109/00365521.2014.968860 PMID: 25310139
47. Kielland KB, Delaveris GJ, Rogde S, Eide TJ, Amundsen EJ, Dalgard O. Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: a longitudinal long-term cohort study. Journal of hepatology. 2014; 60(2):260-6. doi: 10.1016/j.jhep.2013.09.022 PMID: 24096048
48. Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Seminars in liver disease. 2011; 31(4):331-9. doi: 10.1055/s-0031-1297922 PMID: 22189973
49. Bramness JG, Kornor H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug and alcohol dependence. 2007; 90(2-3):203-9. doi: 10.1016/j.drugalcdep.2007.03.008 PMID: 17478058
50. Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nature reviews Gastroenterology & hepatology. 2011; 8(4):212-23.
51. Grebely J, Matthews GV, Lloyd AR, Dore GJ. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2013; 57(7):1014-20.
52. Grebely J, Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral research. 2014; 104:62-72. doi: 10.1016/j.antiviral.2014.01.002 PMID: 24468275
53. Hickman M, De Angelis D, Vickerman P, Hutchinson S, Martin NK. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Current opinion in infectious diseases. 2015; 28(6):576-82. doi: 10.1097/QCO.0000000000000216 PMID: 26524330